Date: 2015-02-23
Type of information: Grant
Company: The University of Manchester (UK) Cobra Biologics (Sweden)
Investors: Innovate UK (UK)
Amount: £217 000
Funding type: grant
Planned used: The joint project, PeriTune, is to develop a protein expression optimisation platform for the robust production of biologics. The platform will utilise the tuneable gene expression control technology RiboTite, developed at The University of Manchester, coupled with the expertise in bioprocessing scale up at Cobra Biologics. The RiboTite technology operates at the level of translation initiation and permits cellular-level tuneable control of gene expression. Here, uniquely, this capability will be used to match expression to the periplasmic secretion capabilities of E. coli production cells. At high levels of recombinant protein overexpression the secretion pathways can become overloaded, affecting product titres and cell viability. Clones developed through the optimisation platform at The University of Manchester will be validated, demonstrated at scale, and assessed for manufacturability within Cobra Biologics. The PeriTune project will allow Cobra Biologics to investigate the use of the RiboTite technology in controlling levels of secreted protein production in E.coli, and also the manufacturing robustness of the system during fermentation scale up.
Others: * On February 23, 2015, Cobra Biologics and The University of Manchester have been awarded collaborative funding of £217K as one of only 23 projects which will share almost £20M from the Innovate UK / Biotechnology and Biological Sciences Research Council (BBSRC) supported Industrial Biotechnology Catalyst. This grant will support the joint project, PeriTune.
Therapeutic area: Technology - Services
